Ignite Creation Date:
2025-12-24 @ 10:33 PM
Ignite Modification Date:
2026-03-01 @ 5:54 PM
Study NCT ID:
NCT03634735
Status:
COMPLETED
Last Update Posted:
2020-10-29
First Post:
2018-06-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Thiamin Against Robust IBD Fatigue
Sponsor:
University of Aarhus
Organization:
Study Overview
Official Title:
Thiamin Against Robust IBD Fatigue
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with Inflammatory Bowel Disease (IBD), disease in remission and chronic fatigue will receive oral Thiamine treatment for 4 weeks in a RCT, cross-over study.
Detailed Description:
Patients with Inflammatory Bowel Disease (IBD), disease in remission and chronic fatigue will receive high dose oral Thiamine treatment for 4 weeks in a RCT, cross-over study.
After the high dose treatment period, participants will be randomized to 3 months treatment with Thiamine 300mg/day or placebo.
After the high dose treatment period, participants will be randomized to 3 months treatment with Thiamine 300mg/day or placebo.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: